NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

| More on:
A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.

Image source: The Motley Fool

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NIB Holdings Limited (ASX: NHF) shares have been outperforming this year and delivered very strong returns for shareholders.

Since the start of the year, the private health insurer's shares are up a sizeable 24%.

This compares very favourably to the benchmark ASX 200 index, which is up approximately 6.5% over the same period.

Can NIB shares keep rising?

Unfortunately, the team at Macquarie thinks that the run is coming to an end, particularly given that a new headwind is emerging for one of NIB's businesses.

That headwind is the Department of Health preparing to respond to an Issues Paper assessing the level of commissions paid to third party agents.

The Department of Health is looking at the Overseas Student Health Cover market and is testing three items. Of particular interest to Macquarie is a potential cap on payments to third-party agents for distributing insurance policies to students.

While Macquarie notes that commission caps could make larger university contracts more valuable to NIB, it suspects that it could pressure the business model for agents.

Commenting on this potential headwind, the broker said:

A ~12% commission cap could be an outcome (some arrangements are currently 30%-40%). While insurer margins could increase in the short term, sales driven businesses (not supported by ancillary offerings) could struggle. Notably, NHF relies on sales agents (particularly in India), which could be at risk, while being underweight university contracts. Additionally, as one of the few insurers offering a full product lifecycle, slower sales to Students would negatively impact NHF's higher-margin Workers' policyholders.

We estimate Students represented ~33% / ~20% of Revenue / UOP in NHF's IIHI division in FY24. This would equate to ~2.2% of Group UOP, before accounting for stranded costs and conversion into Workers policies.

Shares tipped to fall

The note reveals that Macquarie has reaffirmed its underperform rating and $5.55 price target on NIB's shares. Based on its current share price of $6.87, this implies potential downside of 19% for investors over the next 12 months.

And while a ~4% dividend yield is expected over the next 12 months, this only limits the total negative return to approximately 15%.

Commenting on its underperform rating, the broker said:

Underperform. With multiple sub-divisions now experiencing operational headwinds, we retain our cautious outlook.

In light of this, investors may want to keep their powder dry for the time being and wait for a better entry point or for its headwinds to clear and tailwinds to emerge.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group and NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor looks unsure.
Healthcare Shares

Should you buy the rebound in CSL shares today?

Two leading experts deliver their verdicts for CSL shares.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Up 129% in a year, are Pro Medicus shares a buy ahead of tomorrow's FY 2025 results?

A leading expert delivers his verdict on the surging Pro Medicus share price.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Poor prognosis: Expert says sell these 2 ASX 200 healthcare giants now

Jed Richards from Shaw and Partners has a sell rating on both healthcare shares.

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Why this ASX 200 stock could jump 25%

Bell Potter has good things to say about this stock.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Guess which ASX All Ords stock just crashed 23% on earnings miss

Investors are sending the ASX All Ords stock tumbling on Friday. But why?

Read more »

Lab worker puts hands in the air and dances around.
Healthcare Shares

Guess which ASX 300 stock just jumped 12% on FDA approval

Investors are piling into the ASX 300 stock following big US news.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Healthcare Shares

Broker says Telix shares could surge 80% higher after selloff

Let's see what Bell Potter has to say about this beaten down healthcare share.

Read more »

A doctor looks unsure.
Dividend Investing

Down 11% in a year, are CSL shares now a good income buy?

CSL shares have faced headwinds from potential US pharmaceutical tariffs.

Read more »